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The discovery of hepcidin clariﬁed the basic mechanism of the control of systemic iron
homeostasis. Hepcidin is mainly produced by the liver as a propeptide and processed
by furin into the mature active peptide. Hepcidin binds ferroportin, the only cellular iron
exporter, causing the internalization and degradation of both. Thus hepcidin blocks iron
export from the key cells for dietary iron absorption (enterocytes), recycling of hemoglobin
iron (the macrophages) and the release of storage iron from hepatocytes, resulting in the
reduction of systemic iron availability. The BMP/HJV/SMAD pathway is the major regulator
of hepcidin expression that responds to iron status. Also inﬂammation stimulates hepcidin
via the IL6/STAT3 pathway with a support of an active BMP/HJV/SMAD pathway. In some
pathological conditions hepcidin level is inadequately elevated and reduces iron availability
in the body, resulting in anemia. These conditions occur in the genetic iron refractory
iron deﬁciency anemia and the common anemia of chronic disease (ACD) or anemia of
inﬂammation. Currently, there is no deﬁnite treatment for ACD. Erythropoiesis-stimulating
agents and intravenous iron have been proposed in some cases but they are scarcely
effective andmay have adverse effects. Alternative approaches aimed to a pharmacological
control of hepcidin expression have been attempted, targeting different regulatory steps.
They include hepcidin sequestering agents (antibodies, anticalins, and aptamers), inhibitors
of BMP/SMAD or of IL6/STAT3 pathway or of hepcidin transduction (siRNA/shRNA) or
ferroportin stabilizers. In this review we summarized the biochemical interactions of the
proteins involved in the BMP/HJV/SMAD pathway and its natural inhibitors, the murine and
rat models with high hepcidin levels currently available and ﬁnally the progresses in the
development of hepcidin antagonists, with particular attention to the role of heparins and
heparin sulfate proteoglycans in hepcidin expression and modulation of the BMP6/SMAD
pathway.
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HEPCIDIN DISCOVERY AND PROPERTIES
Hepcidin was independently discovered in the years 2000–2001 by
various groups. Krause et al. (2000) isolated from human blood
ultraﬁltrate a 25-residue peptide with antimicrobial activity that
they named LEAP-1 (liver-expressed antimicrobial peptide 1). In
the same period Pigeon et al. (2001) identiﬁed an iron-regulated
gene that encoded for the LEAP-1 with high expression in the
liver, and much lower expression in the kidney, adipose tissue,
heart, and brain. Park et al. (2001) characterized a cysteine-rich
peptide and named it hepcidin (hepatic bactericidal protein) for
its hepatic origin with a structure typical for an antimicrobial
activity. They found homologous cDNAs in the liver of vari-
ous species from ﬁsh to human. A central role of hepcidin in
systemic iron homeostasis was soon unambiguously recognized
by the ﬁnding that inactivation of its gene was associated with
severe iron overload in the liver and pancreas (Nicolas et al., 2001).
The ﬁnding was serendipitous, since the knockout construct was
Abbreviations: BMP, bone morphogenetic protein; SMAD, sons of mothers against
decapentaplegic; STAT, signal transducer and activator of transcription; IL-6,
interleukin-6; LPS, lipopolysaccharides; GAG, glycosaminoglycan.
aimed at deleting USF2 gene (upstream stimulatory factor 2) but
it also removed the hepcidin adjacent genes. A following speciﬁc
USF2 knockout mouse had normal hepcidin and iron, while the
speciﬁc inactivation of hepcidin gene caused iron overload (Nico-
las et al., 2002). The importance of hepcidin was conclusively
demonstrated by the ﬁnding that transgenic mice overexpress-
ing the peptide showed a severe and often lethal anemia (Nicolas
et al., 2003). The initial excitement about hepcidin as a central
player in the communication of body iron stores to the intesti-
nal absorptive cells (Fleming and Sly, 2001) was further sustained
by the ﬁnding that patients with homozygous mutations in the
hepcidin gene were affected by severe juvenile hemochromatosis
(Roetto et al., 2003). The following years were dedicated to the
characterization of the gene, its product and the regulation of its
expression.
In human the hepcidin gene is in chromosome 19 and
encodes a precursor prepropeptide of 84 amino acids that is
processed by two sequential cleavages. The ﬁrst of the signal
sequence and the second of the pro-region to produce the mature
peptide of 25 amino acids (aa). Furin, a major member of
the family of prohormone convertases, is the enzyme involved
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in the processing, and it recognizes the consensus sequence
(QRRRRR↓DTHF) conserved in mammal and ﬁsh hepcidins
(Shike et al., 2004; Valore and Ganz, 2008; Figure 1A). Chemical
or siRNA-mediated inhibition of furin prevents hepcidin mat-
uration but not its secretion from the cell (Valore and Ganz,
2008). The processing may be more complex, since two addi-
tional hepcidin N-terminal truncated forms of 22 and 20 aa
were originally described (Figure 1A). Hepc-25 and hepc-20 are
formed intracellularly and possibly processed in the Golgi appa-
ratus by furin-like proteases and both secreted in the blood.
Whereas hepc-22 is present only in urine (Park et al., 2001).
The role of hepc-20 and hepc-22 is not clear. The NMR struc-
ture of the mature hepcidin 25 was obtained from the refolded
synthetic peptide (Jordan et al., 2009). It consists of two short
β-strands stabilized by interstrand disulﬁde bonds (Figure 1B). It
has amphipathic properties with cationic charges and hydropho-
bic surface like most of antimicrobial peptides (Figure 1C),
however, the antimicrobial activity of human hepcidin is low
and probably not critical. Mouse has two different hepcidin
genes (hepc-1 and hepc-2) but only hepc-1 is related with iron
metabolism.
Although mammalian hepcidin attracted most interest, it
should be mentioned that hepcidin has been described also in
ﬁshes, where the size and cysteines are conserved, but the overall
amino acid sequence identity with the human one is only 50%
(Nemeth and Ganz, 2006). The role of ﬁsh hepcidin in systemic
iron regulation is unclear.
REGULATION OF HEPCIDIN EXPRESSION IN THE LIVER
Most of the regulation of hepcidin expression in the liver occurs
at transcriptional level and it is modulated by iron status, inﬂam-
mation, and hypoxia (Nemeth and Ganz, 2006). Iron supplemen-
tation to the animal readily stimulates liver hepcidin mRNA, but
this does not occur in cultured cells, of hepatic or non-hepatic
lineage, suggesting an indirect mechanism of iron sensing. A
breakthrough for the understanding of the regulatory mecha-
nism was the ﬁnding that mice with liver conditional inactivation
of the SMAD4 gene developed early and severe liver iron over-
load, since they did not express detectable hepcidin mRNA even
after induction with iron and inﬂammatory stimuli (Wang et al.,
2005). SMAD4 is the key player of the TGF-beta/BMP signaling
transduction that involves serine kinases, and phosphorylation of
FIGURE 1 | Hepcidin structure. (A) Hepcidin is encoded as a precursor
prepropeptide of 84 amino acids, it is processed by two sequential
cleavages. The ﬁrst cleavage is for removing the signal peptide and the
second the pro-peptide to produce the mature peptide of 25 amino acids.
Furin is the convertase that recognizes the consensus sequence
QRRRRRDTHF forming three different hepcidin (25; 22 and 20). (B) The
structure of hepcidin-25 is characterized by two short β-strands stabilized by
four interstrand disulﬁde bonds. (C) The view of space-ﬁlling diagram of
hepcidin-25 indicating cationic charges (blue; the right ﬁgure) and
hydrophobic (white) side with vicinal disulﬁde (yellow) and the C-terminus in
red (the left ﬁgure). Structures were generated with GRASP and derived
from Hunter et al. (2002).
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SMAD members to form complexes with SMAD4. These com-
plexes enter the nucleus and bind the responsive elements of the
target genes for their activation. The centrality of this regulatory
pathway was conﬁrmed by the ﬁnding that hemojuvelin (HJV),
which is mutated in severe juvenile hemochromatosis (Papaniko-
laou et al., 2004), acts as a co-receptor of the BMP/SMAD pathway
in the liver (Babitt et al., 2006). The 20 different members of
the BMP family are produced by various cell types and have
different functions, including osteogenesis, embryogenesis, and
differentiation. Initial experiments used the osteogenic BMP2 and
BMP4 to stimulate hepcidin expression in cultured hepatic cells
(Truksa et al., 2006). In vitro studies showed that also BMP5, 7
and 9 can induce SMAD pathway and hepcidin expression in pri-
mary hepatocytes (Truksa et al., 2006) but after the ﬁnding that
BMP6 is modulated by systemic iron and, more important, that
BMP6−/− mice suffer of severe iron overload and the lack of
liver hepcidin it was accepted that BMP6 is the major regulator
of hepcidin expression (Andriopoulos et al., 2009; Meynard et al.,
2009). The dimers of type-II and type-I BMP-receptor participate
in BMP/SMAD signaling together with various co-receptors and
inhibitors. In the hepatic signaling, ALK2/ALK3 are the predom-
inant BMPR type-I, and ActRIIA is the predominant type-II (Xia
et al., 2008) and, of note, the GPI-anchor protein HJV acts as an
essential co-receptor for hepcidin expression (Babitt et al., 2006).
HJV is a member of the repulsive guidance molecule (RGM) fam-
ily, which includes RGMa and DRAGON (RGMb), GPI-anchored
proteins apparently involved in BMP signaling in different tissues
(Corradini et al., 2009). HJV is expressed in skeletal and heart
muscle and particularly in the liver where acts as an essential
regulator of the signaling. It is also processed by the convertase
furin into a soluble form that may act as a decoy and reduce
hepcidin expression (Kuninger et al., 2008; Silvestri et al., 2008).
It is degraded by the liver-speciﬁc serine protease Matriptase-
2 (MT2, alias TMPRSS6; Silvestri et al., 2009). Inactivation of
MT2 in mice and in human results in hepcidin increase and
causes iron refractory iron deﬁciency anemia (IRIDA; Du et al.,
2008; Finberg et al., 2008; Folgueras et al., 2008). Neogenin is
another transmembrane protein involved in the signaling. It is
ubiquitously expressed and interacts with RGM proteins. In the
liver it interacts with both HJV and MT2 and may be required
for the proper assembly of HJV-BMP ligand-BMPR-I/BMPR-II
complex to initiate the BMP signaling and induce hepcidin expres-
sion (Zhang et al., 2005; Enns et al., 2012). Neogenin may also
form a ternary complex with MT2 and HJV that facilitates HJV
cleavage by MT2. Thus Neogenin can stimulate or suppress the
BMP signaling by favoring the assembly of BMPs/HJV/BMPR
complex or by facilitating MT2 activity, respectively (Zhao et al.,
2013). A point not yet fully elucidated regards the involvement
of HFE and TFR2. These genes are mutated in type I and III
hemochromatosis, both characterized by relatively low hepcidin
levels. HFE can bind both TFR1 and TFR2 and a model has been
proposed in which HFE and TFR2 act as a complex and contribute
to the complete activation of BMP/SMAD pathway (Gao et al.,
2010). Other studies indicated that HFE and TFR2 are involved
in the activation of MAPK, a pathway that cross talks with the
BMP/SMAD and contribute to hepcidin expression (Poli et al.,
2010; Figure 2A).
Regulation of the BMP/SMAD signaling occurs also after the
phosphorylation of SMAD1/5/8 and ensures ﬁne tuning at cytoso-
lic level. SMAD7 antagonizes the recruitment of SMAD4 and the
translocation of SMAD1/5/8-SMAD4 complex into the nucleus
and recently it has been demonstrated that in hepcidin promoter
there is a SMAD7-binding motif for a direct inhibition of the
promoter (Mleczko-Sanecka et al., 2010).
Another well characterized pathway of hepcidin regulation
involves the inﬂammatory cytokine IL6 that binds its speciﬁc
receptor and activates JAK1/2 to phosphorylate STAT3. The phos-
phoSTAT3 translocates into the nucleus and binds the STAT3
response element (STAT3-RE) in hepcidin promoter, stimulating
its transcription (Verga Falzacappa et al., 2007). This pathway can
be activated by other cytokines including IL22 and Oncostatin-M
which also increase hepcidin transcription, (Chung et al., 2010;
Armitage et al., 2011). This inﬂammatory signaling relies on the
BMPs/SMAD pathway to trigger hepcidin expression; in fact
SMAD4-KO mice do not respond to the stimulation of IL6 (Wang
et al., 2005). Activin-B, which belongs to the TGF-beta family,
was shown to be stimulated by inﬂammation and to induce hep-
cidin via the BMP/SMAD pathway, thus it may cooperate and
enhance the IL6-dependent stimulation and it could represent
a connecting component between iron status and inﬂammation
(Besson-Fournier et al., 2012; Figure 2B).
THE HEPCIDIN–FERROPORTIN AXIS
The only known receptor for hepcidin is ferroportin, which is
the sole cellular iron exporter. Ferroportin (FPN) is expressed by
enterocytes of the duodenum, by macrophages that process effete
RBC and by liver, and is responsible for the release of iron to
transferrin, in a mechanism that needs the assistance of a cop-
per ferroxidase such ceruloplasmin or haephestin (Nemeth et al.,
2004; Hentze et al., 2010). The iron export activity of ferroportin
is essential for the regulation of systemic iron homeostasis, but its
biochemical properties and the mechanism of iron transport are
not well characterized. It is a 62.5 kDa protein with 12 transmem-
brane domains, the N-terminus and possibly also the C-terminus
are cytosolic (Liu et al., 2005; Figure 3A). Mutation in FPN gene
lead to type IV hemochromatosis (ferroportin disease), which is
dominantly transmitted. This has suggested that ferroportin forms
functional dimers (De Domenico et al., 2005), but direct studies
indicated that it is amonomer (Montosi et al., 2001; Liu et al., 2005;
Wallace et al., 2010; Figure 3B). The ferroportin mRNA has an IRE
on the 5′UTR that may be responsible for its iron-dependent reg-
ulation (Muckenthaler, 2008). However, the major regulatory step
occurs at a post-translational level caused by hepcidin (Nemeth
et al., 2004). In fact the binding of hepcidin causes ferroportin
internalization and degradation, with the effect to reduce systemic
iron availability (Ganz andNemeth, 2012). Further studies showed
that Hepcidin-25 binds an extracellular loop of FPN adjacent to
the cytosolic loop containing the two tyrosines required to signal
internalization (Nemeth et al., 2006). The binding involves disul-
ﬁde bridging with FPN Cys326 (Fernandes et al., 2009; Figure 3A),
ferroportin ubiquitination prevalently at the level of lysines
present in a third cytoplasmic loop of ferroportin (possibly Lys
229 and 269), and proteasomal degradation (Qiao et al., 2012;
Figure 3B).
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FIGURE 2 | Intracellular signaling pathways for hepcidin expression.
(A) Iron status stimulates hepcidin expression through BMP6 and Holo-Tf.
This signaling involves BMP receptor, HJV (BMPco-receptor), TMPRSS6 (MT2,
a negative regulator), Neogenin, TfR2, and HFE (sensors of Holo-Tf
saturation). Intracellularly this multiprotein complex triggers the activation of
SMAD1/5/8 and SMAD4 components and possibly ERK1/2. (B)The
inﬂammatory status triggers the hepcidin expression through IL6/STAT3
pathway and ActivinB that activates SMAD1/5/8 pathway.
LOCAL EXPRESSION OF HEPCIDIN IN CNS
Liver is the major producer of hepcidin, and the ﬁne tuning
of its expression sets the level of circulating hepcidin to govern
systemic iron homeostasis. Various other tissues express hep-
cidin mRNA and protein suggesting the presence of autocrine
or paracrine circuits that may contribute to the regulation of
local iron distribution. This may be particularly important
in the central nervous system (CNS) that is separated from
the rest of the body. The blood–brain barrier (BBB) and the
blood/CSF barrier are the major sites of iron exchange with
the periphery (Rouault et al., 2009; Figure 4A). These barriers
act as semipermeable cellular gates characterized by tight junc-
tion and specialized transcellular carriers mediating inﬂux or
efﬂux. Transferrin and its receptor take part in most of iron
transfer, but the details on the regulatory mechanism are miss-
ing. Of interest is that cells of the blood/CSF barrier express
proteins of the hepcidin/ferroportin axis (Figure 4B). The imag-
ing techniques and histology of the different areas of the brain
showed that regions with neurodegeneration exhibit also iron
accumulation in pathological conditions such as Alzheimer’s dis-
ease (AD; Bishop et al., 2002), Parkinson’s disease (PD; Berg
et al., 2001; Zecca et al., 2004), and neurodegeneration with brain
iron accumulation (NBIA; Hayﬂick, 2006), while restless leg syn-
drome (RLS) is associated with reduced CNS iron content (Clardy
et al., 2006). There is evidence that the hepcidin/ferroportin axis
might play a role in the iron decompartmentalization occurring
in these disorders. In fact, not only hepcidin and ferroportin,
but also the accessory proteins in iron transfer ceruloplasmin,
hephaestin and DMT1, and those involved in hepcidin regu-
lation (BMPs, IL6, Tfr2) are expressed and regulated in the
brain (Figure 4B). Hepcidin and ferroportin mRNA and pro-
tein were detected in different murine and human cerebral areas
(Clardy et al., 2006; Zechel et al., 2006) and hepcidin intraventric-
ular injection resulted in downregulation of FPN protein (Wang
et al., 2010b). Systemic iron inﬂammation or acute iron overload
induced a signiﬁcant increase in cerebral hepcidin expression in
mice and rats (Malik et al., 2011; Wang et al., 2011; Sun et al.,
2012) thus suggesting that the machinery controlling hepcidin
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FIGURE 3 |Theoretical model of human ferroportin. (A) A 2-dimensional
model of ferroportin, based on the model of (Liu et al., 2005;Wallace et al.,
2010), modiﬁed fromWallace et al. (2010). It shows a 12-transmembrane
(TM) domain structure with both N- and C-terminus cytosolic. In yellow is
marked Cys326 fundamental for hepcidin–ferroportin binding and in green
Lys229 and 269 essential for ferroportin ubiquitination. (B)Theoretical
models of ferroportin dimer and monomer after the binding of hepcidin.
Both of them include the proteasoma degradation of ubiquitinated
ferroportin.
expression in the brain is similar to the hepatic one. Novel evi-
dence suggests that perturbation of the cerebral hepcidin-FPN
axis may contribute to local deregulation of iron homeosta-
sis. They include an increase of hepcidin in the brain in a
murine model of cerebral ischemia (Ding et al., 2011), and a
reduction of both ferroportin and hepcidin detected in lysates
obtained from AD patients (Raha et al., 2013). Furthermore, calo-
rie restriction prevented both the increase in cerebral hepcidin
mRNA and the impairment of learning and memory observed
in an experimental model of aging (Wei et al., 2014). Fur-
ther characterization of the machinery controlling iron balance
in the brain is needed, but attention should be given at the
possible modulation of hepcidin expression in CNS caused by
pharmacological intervention aimed at regulating systemic iron
homeostasis, in particular those involving molecules that can pass
the BBB.
IRON DISORDERS IN WHICH HEPCIDIN IS PATHOLOGICALLY
UPREGULATED
Hepcidin is the hormone of iron and inﬂammation and its dereg-
ulation occurs in all iron related disorders, including the ones
characterized by iron restriction and anemia in which hepcidin
is abnormal (Ganz and Nemeth, 2011). Elevated hepcidin lev-
els are associated with secondary iron overload, genetic IRIDA,
chronic infectious and inﬂammatory diseases resulting in anemia
of inﬂammation (AI). The ﬁnding that hepcidin is upregu-
lated by the inﬂammatory cytokine IL6 (Verga Falzacappa et al.,
2007) contributed to explain the anemia of chronic diseases
(ACD) alias AI. This occurs in a variety of disorders, like infec-
tions, chronic kidney diseases (CKDs), rheumatoid arthritis, and
cancer (Wang et al., 2012) including multiple myeloma (Maes
et al., 2010), a severe malignant disorder of plasma cells. Cur-
rently ACD therapy includes erythropoiesis-stimulating agents
and intravenous iron (Goodnough et al., 2010), which may have
adverse effects and are scarcely effective (Glaspy, 2012; Fung
and Nemeth, 2013). For example inﬂammation often induces
erythropoietin resistance (Macdougall and Cooper, 2002). Alter-
native treatments have been proposed and hepcidin antago-
nists seem to be the best candidates to treat these disorders
(Wang et al., 2012).
THERAPEUTIC APPROACHES TO NEUTRALIZE HEPCIDIN
EXCESS
The mechanisms involved in the regulation of hepcidin expres-
sion are complex and partially known, and the approaches can
use different targets to downregulate hepcidin or its function, as
described in recent reviews (Sun et al., 2011; Fung and Nemeth,
2013).
BMP/BMPR COMPLEX
One obvious target is the BMPs/BMPR complex. This was ini-
tially tested by developing anti-BMP6 antibodies to abolish the
interaction between BMP6 and its receptors. The iron-restricted
anemia of HFE transgenic mice due to high hepcidin was effec-
tively cured with 10-day treatment with anti-BMP6 (Corradini
et al., 2010). However, similar treatment was not effective in ACD
possibly due to the expression of other BMPs, as it occurs in
multiple myeloma with high BMP2 (Maes et al., 2010). Another
target is HJV, the major co-receptor of the BMP/SMAD sig-
naling. A treatment of healthy rodents with soluble HJV.Fc
blocked SMAD phosphorylation, decreased hepcidin expression,
mobilized splenic iron content and increased serum iron lev-
els (Babitt et al., 2007). In an ACD rat model, a long 4-week
treatment showed a recovery of anemia with the inhibition
of SMAD1/5/8 phosphorylation; increase of splenic ferroportin
levels and of serum iron (Theurl et al., 2011). Another promis-
ing approach is to block the phosphorylation of type I BMP
receptor. The initially tested molecule was dorsomorphin, a
non-speciﬁc kinase inhibitor (Yu et al., 2008), and then a more
selective BMP inhibitor, coded LDN-193189 (Cuny et al., 2008),
in animal models. A 4-week treatment of anemic rats with
chemically induced arthritis reduced hepatic hepcidin mRNA lev-
els, increased serum iron concentration, increased ferroportin
expression in splenic macrophages, and improved hemoglobin
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FIGURE 4 | Brain iron regulation. (A)The blood–brain barrier and blood–CSF
barrier are the two major sites of iron exchange with the periphery
(Edelhauser et al., 2010). They act as a diffusion barrier to large and hydrophilic
molecules. Small, lipophilic molecules or toxic metabolites are delivered
through speciﬁc carrier mediating inﬂux or efﬂux. The structure responsible
for the correct working of these barriers is the tight junction (black rectangle);
transferrin and its receptor are responsible for most of the iron uptake into
CNS [modiﬁed from Edelhauser et al. (2010)]. (B) Schematic representation of
an ependymal cell in the blood–CSF barrier. This cell type, like other cell types
of the CNS, express proteins involved in hepcidin expression and iron
regulation, ferroportin (for export to CSF), TfR2, HFE, BMPr, HJV, IL6r, DMT1.
Inﬂammatory stimuli, iron deregulation, or other effectors that alter hepcidin
expression may contribute to modify brain iron homeostasis and
compartmentalization. Reprinted with permission from Choi and Kim (2008).
levels and hematocrit (Theurl et al., 2011). It was also effective
in treating mice with acute inﬂammatory anemia induced by
turpentine injections (Steinbicker et al., 2011). A limit of this
chemical inhibition of hepcidin is the lack speciﬁcity for BMP
inhibition, since it can also potently inhibit VEGF and compo-
nents of the MAPK/ERK pathway and show toxicity (Vogt et al.,
2011). Liver is the organ most easily targeted by siRNAs, and the
studies on the silencing of HJV and TfR2 are ongoing (Akinc et al.,
2011).
HEPARIN
The observation that BMPs are heparin binding molecules and
that heparin modiﬁes the osteogenic activity of BMP2/4 stimu-
lated (Poli et al., 2011) to verify the effect of heparin on hepcidin
expression. It was shown that commercial heparins are potent hep-
cidin inhibitor in vitro in HepG2 cells and in vivo in healthy mice
and that act by inhibiting the BMP6/SMAD signaling. Heparins
are well characterized molecules with some 70 years of clinical
experience, and appealing drugs for the treatment of anemia. The
major drawback of their strong anticoagulant activity can be over-
come. In fact the anticoagulant activity is mostly linked to high
binding afﬁnity to antithrombin, which is limited to a speciﬁc
pentasaccharide, named AT-bs, absent in some heparins, that can
be chemically modiﬁed (Figure 5). The main modiﬁcations to
reduce or abolish the anticoagulant property are summarized in
Figure 5B and they are: N-desulfation or N-acetylation, 2-/6-
O-desulfation, supersulfation or, more simply, the treatment of
heparins by reduction and oxidation, to obtain the so called RO-
heparins (Casu et al., 2002). This splits the glycol bonds, increasing
molecular ﬂexibility and improving the interaction with targets
other than antithrombin. These glycol-split heparins retain var-
ious biological functions, including anti-heparanase activity that
reduces tumor growth and metastasis in animal models (Ritchie
et al., 2011). Some of these compounds are in clinical trials and
they have shown little or no toxicity. These glycol-split heparins
showed to be potent hepcidin inhibitors in vitro, in HepG2 cells
and primary hepatocytes, and in vivo in mice (Poli et al., 2014).
In vivo these heparins reduced hepcidin in 6 h with concomitant
increase of serum iron and decrease of spleen iron. They inhibited
hepcidin also after an acute lipopolysaccharide (LPS) stimulation,
and in a mouse model of anemia induced by a single injection of
heat-killed Brucella abortus (HKBA) these heparins improved the
recovery of anemia. The available data indicate that heparins act
by sequestering of BMP6 and inhibiting the SMAD1/5/8 signal-
ing. These ﬁndings also indirectly suggest a role of liver heparan
sulfate proteoglycans (HSPGs) in hepcidin regulation. The main
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FIGURE 5 | Heparin structure. Heparin is a sulfated polysaccaride
belonging to the glycosaminoglycans family. It is composed of
disaccharide units formed by one uronic acid (L-iduronic acid, IdoA, or
D-glucuronic acid, GlcA) and one amino sugar (D-glucosamine, GlcN). IdoA is
prevalently sulfated at the position 2 and GlcN is prevalently N -sulfated (or
N -acetylated) and 6-O-sulfated. The main structure of heparin is composed by
70% of N -sulfated region (NS, IdoA2SO3 -GlcNSO36SO3), N -acetylated
region (NA, GlcA-GlcNAc) and mixed NA/NS (GlcA-GlcNSO3;A). (B) An
important region for the anticoagulant property of heparins is the
antitrombin-binding domain (AT-bs), present in no more than one third of the
chain, characterized by the pentasaccharidic sequence: GclNAc6SO3–
GlcA-GlcNSO3-6SO3–IdoA2SO3-GlcNSO3.6SO3. Non-anticoagulant heparins
can be obtained by removing the AT-bs or by modifying one or more residues
essential for the binding to AT. For example: N -desulfation and 2-O or
6-O-desulfation cause a dramatic drop in the anticoagulant activity as
N -acetylation. Other possibilities include the reduction of carboxyl groups of
GlcA residue and the cleavage of the bond between its two hydroxyl groups
to obtain the glycol-split heparins.
structure of heparin is composedby 70%of N-sulfated region (NS,
IdoA2SO3- -GlcNSO36SO3), N-acetylated region (NA, GlcA-
GlcNAc) andmixedNA/NS (GlcA-GlcNSO3; Figure 5A). Heparin
is structurally analogous to the heparan sulfates (HSs) exposed
on the surface of all cells that are known to modulate criti-
cal biological events, such as embryonic development, growth
regulation and maintenance of normal tissue structure and func-
tion (Turnbull et al., 2001). In fact they can act as “receptors”
for circulating proteins, including several cytokines and angio-
genic growth factors (Casu et al., 2010). Heparin is utilized as a
model to study the interaction of molecules with cellular hep-
aran sulfates and to modulate their biological activity (Rusnati
et al., 2005). In fact it was recently demonstrated that HSPGs
act as coreceptors of BMP2 and BMP4 in facilitating receptor
oligomerization (Kuo et al., 2010). The consequences of the BMPs
binding to HSPGs vary, depending on the BMP member, cell type
targeted and if HSPGs are cell-associated (co-receptor action)
or in a free form (antagonist effect). Accordingly, alteration of
cell-associated HSPGs by heparinases or by chlorate treatments
reduced (Irie et al., 2003) or increased BMP signaling (Jiao et al.,
2007). Interestingly, the HS in the liver are highly sulfated, and
their inactivation by conditional-KO of key enzymes has effects
on lipid homeostasis, but hepcidin has not been analyzed yet
(Stanford et al., 2010).
IL6/STAT3 AXIS
Inﬂammation induces hepcidin expression mainly through
IL6/STAT3 pathway, which can be blocked by anti-IL6 antibody.
Siltuximab, an anti-IL6 monoclonal antibody drug used in clinic,
was shown to be effective in reducing hepcidin expression in
patients with Castleman’s disease (CD) and in improving their
anemia (van Rhee et al., 2010). The antibody was used also in
patients with renal cell carcinoma and multiple myeloma result-
ing in a decrease of hepcidin and an increase of hemoglobin
(Schipperus et al., 2009; Kurzrock et al., 2013). Tocilizumab is
another antibody in clinical use that acts on IL6 activity by bind-
ing IL6 receptor. CD patients, treated with it, showed a reduction
of serum hepcidin and correction of anemia after 6–12 month
treatment (Song et al., 2010). Tocilizumab was used also in mon-
keys with collagen-induced arthritis with an improvement of
anemia (Hashizume et al., 2010). Chemical agents like AG490
that inhibits STAT3 phosphorylation (Caceres-Cortes, 2008) or
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PpYLKTK that disrupts pSTAT3 dimerization and DNA bind-
ing were investigated in cancers with elevated JAK/STAT activity
(Zhang et al., 2010). Both compounds decrease IL6-dependent
hepcidin expression in differentiated mouse hepatocytes (Fatih
et al., 2010) and AG490 also in vivo in healthy mice (Zhang et al.,
2011).
ANTI-HEPCIDIN AGENTS
A direct approach is to downregulate hepcidin using RNA inter-
ference, taking advantage of the observation that liver is an easy
target for siRNAs. This implies the design of RNAi without off-
target effects, sufﬁciently stable in vivo, biocompatible and with
speciﬁc delivery to liver but not to other organs (Wang et al.,
2010a). High afﬁnity anti-hepcidin antibodies have been pro-
duced and have been engineered to be used in vivo and to analyze
their effects. They improved the inﬂammatory anemia in mice
induced by HKBA only when co-administrated with erythropoi-
etic stimulating agents (Sasu et al., 2010). Fully humanized mAb
against hepcidin (LY2787106) is currently in Phase I for the treat-
ment of cancer-related anemia. Hepcidin blocking proteins were
obtained by modifying the lipocalins, natural proteins that bind
small hydrophobic ligands and cell surface receptors (Flower,
1996; Schlehuber and Skerra, 2005). They were engineered to
produce anticalin PRS-080 that exhibits sub-nanomolar afﬁnity
for human hepcidin. Monkeys treated with PRS-080 showed an
effective iron mobilization, and studies are in progress on anti-
calin safety and tolerability in vivo. Spiegelmers are synthetic
compounds designed to inhibit other molecules. Spiegel means
mirror in German and they are mirror-images L-enantiomeric
oligonucleotides that bind the targets in a manner similar to
antibodies or aptamers. Being nuclease resistant and immuno-
logically passive is suited for in vivo application. NOX-H94 is
a structured L-oligoribonucleotide, that binds human hepcidin
with high afﬁnity, blocking its biological function (Schwoebel
et al., 2013). In monkey NOX-H94 prevented the onset of ane-
mia induced by IL6, in human volunteers, it increased indices
of iron availability and was safe and well tolerated (Riecke et al.,
2012), it also delayed the onset of hypoferremia in volunteers
treated with LPS (Van Eijk et al., 2013). The Phase II clinical
trials with NOX-H94 are ongoing for patients with anemia of
cancer.
ALTERATION OF HEPCIDIN–FERROPORTIN INTERACTION
Antibodies that block ferroportin binding to hepcidin without
affecting its functionality have been described (Leung et al., 2012).
They have been engineered and are now in a Phase I trial. A
high throughput screening approach discovered a thiol modiﬁer
compound (fursultiamine) that prevented ferroportin–hepcidin
interaction sequestering the Cys326-HS residue (essential for
hepcidin binding, Figure 3A) and blocking internalization of fer-
roportin (Fung andNemeth,2013). It could be an interesting agent
to be evaluated in vivo.
ERYTHROID FACTORS
Growth differentiation factor 15 (GDF15), is a member of the
transforming growth factor-β superfamily. It is produced in
erythroid precursor cells and is strongly upregulated in disorders
with increased ineffective erythropoiesis, such as β-thalassemia,
congenital dyserythropoietic anemias. It was shown to downreg-
ulate hepcidin mRNA expression in primary human hepatocytes
(Tanno et al., 2007). A synthetic low molecular weight compound
(K7174) that enhances GDF15 expression in HepG2 cells was
described, and it also reduced hepcidin (Fujiwara et al., 2013).
It was claimed a potential therapeutic option to treat ACD.
However, this contrasts with the ﬁnding that GDF15 deﬁcient
mice have normal hepcidin expression and that GDF15 is not
required to balance iron homeostasis in response to blood loss
(Casanovas et al., 2013). More recently another erythroid factor
with strong effect on hepcidin expression was identiﬁed, it was
named erythroferrone it is stimulated by active erythropoiesis
and it suppresses hepcidin expression in hepatic cells (Kautz et al.,
2013). It is an important potential target for the control of hepcidin
expression.
ANIMAL MODELS OF INFLAMMATORY ANEMIA
The hepcidin antagonists are expected to ﬁnd clinical use mainly
for the treatment of inﬂammatory anemia which, although widely
diffused in clinical practice, has few animal models with different
properties, as recently reviewed (Rivera and Ganz, 2009). Here is
a short description of the ones so far described in past and recent
papers focusing only on the well-known model.
LIPOPOLYSACCHARIDE
Lipopolysaccharide injections in the mice induce an inﬂamma-
tory response, with upregulation of IL6, an increase in Socs3
mRNA, Crp mRNA and hepcidin mRNA and protein and a
decrease in serum iron, but generally do not induce anemia
(Poli et al., 2014). The activation of hepcidin is fast (4–6 h) and
decreases just as quickly. It was shown that anemia could be
induced after a single dose of LPS followed a week later by an
injection of Zymosan A (a preparation from yeast wall). This,
so named ZIGI mouse model, is characterized by high IL6 and
hepcidin, increase in spleen iron content with a decrease of liver
ferroportin and anemia 5 days after Zymosan injection (Lasocki
et al., 2008). The LPS pre-treatment reduces the strong septic
shock-like response triggered by Zymosan A which leads to mul-
tiple organ dysfunctions (Volman et al., 2005). This interesting
model has not been used yet to test the efﬁcacy of hepcidin
antagonists.
TURPENTINE
Turpentine is used to trigger sterile inﬂammatory response in dif-
ferent animal models. Mice treated with a single subcutaneous
injection of turpentine (5 ml/kg) showed induction of hepcidin
and hyperferremia (Sakamori et al., 2010). Anemia was described
after 3-week of daily treatments, that was accompanied by a reduc-
tion of mean corpuscular volume (MCV) and serum iron and a
2–7 fold increase of hepcidin.
HEAT-KILLED Brucella abortus
Heat-Killed Brucella abortus agent is the vaccine to prevent Bru-
cellosis in large animals. When injected in mice induce an inﬂam-
matory response with anemia. It seems the easiest mouse model
of inﬂammatory anemia, and it was used to verify the activity
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of hepcidin antagonists like anti-hepcidin antibodies (Sasu et al.,
2010) and glycol-split heparins (Poli et al., 2014) to improve ane-
mia in vivo. This model of inﬂammatory anemia has been recently
analyzed in depth by the groups of Ganz (Kim et al., 2014) andRiv-
ella (Gardenghi et al., 2014). Both showed thatHKBA-treatedmice
developed a severe anemia, with a nadir after 14 days, followed by
a partial recovery after 28 days. They showed hypoferremia and
iron-restricted erythropoiesis with normal iron stores, shortened
erythrocyte lifespan, and reduced erythropoiesis. The IL6-KO and
hepcidin-KO mice showed a milder anemia and a faster recov-
ery conﬁrming the role of inﬂammation and of hepcidin in the
development of anemia in this model. The anemia has multi-
factorial pathogenesis and hepcidin (that is induced transiently
at 6 h after the HKBA injection) appears to play an important
role in it. It remains to be evaluated if a model closer to ACD in
human can be produced by repeated injections of lower doses of
HKBA.
RAT MODEL OF ANEMIA OF INFLAMMATION
Anemia of inﬂammation can be obtained in rats with differ-
ent treatments that have been used for many years. Nowadays
a good rat model of ACD is obtained with a single intraperitoneal
injection of group A streptococcal peptidoglycan-polysaccharide
(PG-APS) with rhamnose. This treatment caused arthritis with
involvement of multiple joints (Cromartie et al., 1977). Recently
this rat model was analyzed in depth for all iron parameter. After
3 weeks of PG-APS treatment, the rats showed an increase of
serum IL6, hepcidin, and ferritin. Spleen ferroportin decreased,
resulting in a reduction of iron release from macrophages. These
rats develop anemia after 2-week treatment that persists for at least
3 months (Theurl et al., 2009). This anemia has typical features of
human ACD (mild to moderate normocytic and normochromic
anemia) with inﬂammation. This rat model was used to test the
effect of different hepcidin inhibitors with positive results (Theurl
et al., 2011).
Table 1 | Hepcidin inhibitors and corresponding targets.
Inhibitors Target Reference
BMPs/BMPr complex
sHJV-Fc Inhibitors of BMPs/SMAD pathway Babitt et al. (2007), Andriopoulos et al. (2009),Theurl et al. (2011),Wang et al. (2012)
LDN-193189 Inhibitor of phosphorylation of BMPs
receptor type I
Cuny et al. (2008), Steinbicker et al. (2011), Theurl et al. (2011), Wang et al. (2012),
Sun et al. (2013), Saeed et al. (2012)
siHJV, siTfR2 Degradation of HJV or TfR2 mRNA Akinc et al. (2011)
Anti-BMP6 antibody Sequestration of BMP6 Andriopoulos et al. (2009), Corradini et al. (2010), Wang et al. (2012)
Heparin Inhibitors of BMPs/SMAD pathway Poli et al. (2011, 2014)
IL6/STAT3 axis
Anti-IL6r (Tocilizumab) Sequestration of IL6 receptor Song et al. (2010), Hashizume et al. (2010)
Anti-IL6 (Siltuximab) Sequestration of IL6 Schipperus et al. (2009), van Rhee et al. (2010), Kurzrock et al. (2013)
AG490 Inhibitor of STA3 phosphorylation Fatih et al. (2010), Zhang et al. (2011)
PpYLKTK Disruptor of STAT3 dimerization Fatih et al. (2010)
Anti-hepcidin agents
siHep Degradation of hepcidin mRNA Pharmaceuticals, A. ALN-HPN: refractory anemia 2011; Xenon. Isis and Xenon
collaborate to develop antisense drugs against hemojuvelin and hepcidin 2010.
Anti-hepcidin antibody Sequestration of hepcidin protein Sasu et al. (2010)
Anticalin Sequestration of hepcidin protein Congress of the International BioIron Society (BioIron 2011) Vancouver, Canada.
American Journal of Hematology 2011; 86:E48.
Spiegelmers Sequestration of hepcidin protein Schwoebel et al. (2013), Riecke et al. (2012), Van Eijk et al. (2013)
Alteration of hepcidin–ferroportin interaction
anti-ferroportin antibodies Interfering with hepcidin binding to
ferroportin
Leung et al. (2012)
Fursultiamine “Sequestration” of Cys326-HS on FPN
heparin binding site
Fung et al. (2013)
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Modiﬁed adenine-induced kidney disease rat model
Another interesting rat model that develops CKD is obtained
in rodent with a 0.75% adenine diet (modiﬁed adenine) for
3 weeks followed by a control diet for 5 weeks. This protocol
improved survival (90%) maintaining persistent kidney disease
and more severe anemia (Sun et al., 2013). This model was used
to evaluated the effect of the BMP inhibitor LDN-193189 (Sun
et al., 2013). Adenine-treated rats showed increased liver hepcidin
mRNA, decreased serum iron, increased spleen iron content, low
hemoglobin, and low erythropoietin levels. LDN-193189 treat-
ment reduced hepatic hepcidin mRNA, mobilized stored iron and
increased hemoglobin content of reticulocytes.
GENETIC MODEL OF ANEMIA
Iron refractory iron deﬁciency anemia is an autosomal reces-
sive human disorder characterized by congenital hypochromic,
microcytic anemia, very low mean corpuscular erythrocyte vol-
ume, low transferrin saturation, poor response to oral iron
supplementation and partial response to parenteral iron ther-
apy. The mouse models that mimic this disorder were obtained
by two groups (Du et al., 2008; Folgueras et al., 2008). One was
produced by chemically induced mutation that causes splicing
defect in the transmembrane serine protease in gene Tmprss6.
The other one is the KO model produced by a duplication of
an entire region of Tmprss6 gene. In the two models matriptase-
2 is inactivated and is characterized by progressive loss of body
but not facial hair (“mask phenotype”) and microcytic ane-
mia. The mask phenotype results from reduced absorption of
dietary iron and iron retention in duodenal enterocytes, low
ferroportin, and iron deﬁciency anemia caused by high lev-
els of hepcidin (Folgueras et al., 2008). Mask homozygotes are
slightly smaller than their heterozygous littermates, and adult
female homozygotes are infertile whereas male homozygotes
retain fertility. This mouse with a direct implication of hep-
cidin upregulation is probably the best model to study the
long term effects of hepcidin inhibitors with the aim at solving
anemia.
CONCLUSION
This review shows that many laboratories are studying differ-
ent pharmacological means to neutralize hepcidin expression or
activity in order to cure inﬂammatory anemia. They produced a
number of promising approaches, and some of them have been
tested in animal models. Most of them seemed to be effective
in reducing hepcidin expression or activity under acute condi-
tions, but it is still unclear if and how they are efﬁcient in the
treatment of anemia. One of the problems is the lack of ade-
quate animalmodels for inﬂammatory anemia, as indicated above.
Mice models are rather complex, and rat models seems to mimic
more closely the human disease, but the absence of transgenic
rats for hepcidin and inﬂammatory cytokines does not allow
a detailed characterization. Monkeys have been used to induce
inﬂammatory response, but not anemia (Cooke et al., 2013). The
described antagonists (Table 1) originate from different and novel
biotechnological techniques, including humanized anti-hepcidin
antibodies, aptamers, anticalin, siRNAs, and the old traditional
heparin. Some of them are in clinical trials, and perhaps in a few
years we will know if the downregulation of hepcidin really meets
the expectation to improve the anemia in most, or some chronic
diseases. All the antagonists have some advantages and problems.
For example the humanized antibodies have a long half-life in vivo,
but their production is highly expensive. Aptamer and anticalin
inactivate hepcidin, but their fate is unclear. The speciﬁc and efﬁ-
cient delivery of siRNA is complex. Non-anticoagulant heparins
are probably the best known, most convenient and safer agents.
After 70 or more years of use in clinic, most of problems and
side effects of heparins are known. They include thrombocytope-
nia, elevation in serum aminotransferase, hyperkalemia, alopecia
and osteoporosis, but they occur rarely and are transient. The
removal of anticoagulant activity has been resolved and the clin-
ical trials of these agents as hepcidin antagonist should not be far
away. Also the negative effects of treatments for hepcidin inhibi-
tion should be taken into account. They are expected to increase
systemic iron availability and absorption, which may favor iron-
dependent oxidative damage in some parenchymal tissues. If the
pharmacological agents are capable to cross BBB and enter the
brain, they may alter CNS iron homeostasis with unpredictable
effects. In addition, hepcidin is known to have an antimicrobial
activity, which is considered low, but its biological role needs to be
established.
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